IBA white paper: Treating thoracic cancers with proton therapy

Proton therapy

Worldwide, lung cancer is the most common cancer among men in both incidence and mortality, and among women has the third highest incidence and the second in mortality. In the United States, lung cancer remains the number one cause of cancer mortality both in men and women. Lung cancer is categorized as small cell lung cancer and non-small cell lung cancer (NSCLC), with close to 80% of patients presenting with NSCLC. Approximately 15-20% of NSCLC are surgically resectable,1 and about 75% of patients present with locally advanced or metastatic disease at the time of diagnosis.2 For patients with locally advanced disease, and some patients with early stage disease that are unable to tolerate surgery, the current standard therapy is radiation therapy +/- chemotherapy.3 Other cancers of the thorax, such as thymoma and mesothelioma, are also routinely treated with radiation therapy in some scenarios.


Cookies policy

En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des services et des offres adaptés à vos centres d’intérêts.

Gérer vos préférences de cookies

Chez IBA, le respect de votre vie privée reste une priorité.

Les cookies fonctionnels garantissent le fonctionnement du site web. Ils ne peuvent pas être désactivés. En réglant vos préférences, vous pouvez activer et désactiver l’utilisation de ces cookies sur notre site web. Ces réglages ne seront valides que sur l’appareil que vous utilisez actuellement.

Cookies policies